What is Protai?
Founded in 2021, Protai operates at the vanguard of the digital biology revolution. The company specializes in mapping the proteome—the complete set of proteins expressed by an organism—to identify novel therapeutic targets that traditional genomics may overlook. By integrating proprietary AI algorithms with high-throughput proteomics, Protai provides pharmaceutical partners with a granular understanding of disease mechanisms. This capability is essential for addressing complex, multi-factorial diseases where standard therapeutic approaches have historically struggled to achieve efficacy. The company's strategic focus on data-driven drug discovery places it in a unique position to disrupt traditional R&D cycles, offering a more precise and scalable methodology for identifying viable drug candidates.
How much funding has Protai raised?
Protai has raised a total of $20M across 2 funding rounds:
Angel/Seed
$8M
Angel/Seed
$12M
Angel/Seed (2022): $8M with participation from Pitango HealthTech and Grove Ventures Ltd
Angel/Seed (2023): $12M led by Grove Ventures Ltd
Key Investors in Protai
Grove Ventures Ltd
Grove Ventures is a leading early-stage venture capital investment firm with over half-a-billion dollars under management. The company partners early with exceptional Israeli entrepreneurs who believe that the Deep Future is now and are ready to build it.
Pitango HealthTech
Pitango HealthTech is a specialized investment arm focusing on the convergence of healthcare and technology, supporting startups that aim to transform patient outcomes through digital innovation.
What's next for Protai?
With this major enterprise-level funding, Protai is poised to scale its computational infrastructure and expand its collaborative research initiatives. The firm is expected to prioritize the enhancement of its AI-driven discovery engine, aiming to reduce the time-to-market for novel therapeutics. As the company transitions from its foundational development phase into a more mature operational stage, the focus will likely shift toward securing high-value partnerships with global pharmaceutical entities. By scaling its proprietary data assets, Protai aims to solidify its role as an indispensable partner in the global effort to combat complex diseases, ultimately driving long-term value through its unique synthesis of biological insight and machine learning.
See full Protai company page
